Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients

Published:2016-09-22 Issue:3 Volume:57 Page:356-368
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Chung Eun Kyoung¹,Cheatham S. Christian²,Fleming Megan R.³,Healy Daniel P.⁴,Kays Michael B.⁵

Affiliation:

1. Department of Pharmacy; College of Pharmacy; Kyung Hee University; Seoul South Korea

2. Department of Pharmacy; Franciscan St. Francis Health; Indianapolis IN USA

3. Department of Pharmacy; Eskenazi Health; Indianapolis IN USA

4. Division of Pharmacy Practice and Administrative Sciences; James L. Winkle College of Pharmacy; University of Cincinnati Academic Health Center; Cincinnati OH USA

5. Department of Pharmacy Practice; Purdue University College of Pharmacy; Indianapolis and West Lafayette IN USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.812/fullpdf

Reference47 articles.

1. World Health Organization www.who.int/mediacentre/factsheets/fs311/en 2016

2. Ogden CL Carroll MD Fryar CD Flegal KM Prevalence of obesity among adults and youth: United States, 2011-2014. MCHS data brief, no. 219. Hyattsville, MD: National Center for Health Statistics 2015 http://www.cdc.gov/nchs/data/databriefs/db219.htm

3. Trends in obesity among adults in the United States, 2005 to 2014;Flegal;JAMA,2016

4. Public Health England Adult obesity: severe obesity http://www.noo.org.uk/NOO_about_obesity/severe_obesity

5. Obesity and infection;Falagas;Lancet Infect Dis,2006

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current recommendations for antibiotic dosing in obese patients;Vnitřní lékařství;2024-09-04

2. Updated antimicrobial dosing recommendations for obese patients;Antimicrobial Agents and Chemotherapy;2024-05-02

3. Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action;Clinical Pharmacokinetics;2024-01

4. The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development;The Journal of Clinical Pharmacology;2023-11

5. Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese;Open Forum Infectious Diseases;2023-08-28